Skip to main content
. Author manuscript; available in PMC: 2019 Apr 5.
Published in final edited form as: Cell Rep. 2019 Mar 5;26(10):2667–2680.e7. doi: 10.1016/j.celrep.2019.02.023

Figure 1. Generated CDK4/6 Inhibitor-Resistant Cell Lines Have Dramatically Increased CDK6 Protein Expression.

Figure 1.

(A) Flow cytometry analysis of the cell-cycle profile in T47D cells after prolonged treatment (up to 12 weeks) with 100 nM palbociclib to establish resistance. Once resistant, the palbociclib dose was gradually increased from 100 nM (R100) to 500 nM (R500) and cells were monitored until resistance was confirmed by the cell-cycle profile.

(B) Growth rate of resistant T47D cells compared to parental cells.

(C) Real-time qPCR analyzing the fold change in mRNA expression between parental and resistant T47D cells (resistant to 100 nM palbociclib). Data are reported as the means ± SEMs of 3 independent experiments. *p < 0.05, ***p < 0.001.

(D) Whole-genome expression array analysis of the fold change in mRNA expression between parental and resistant T47D cells (resistant to 100 nM palbociclib). Data are reported as the means ± SEMs of 3 independent experiments. *p < 0.05, ***p < 0.001.

(E) Western blot analysis of both T47D and MCF7 resistant cells.